000 02185na a2200241 4500
999 _c2516
_d2516
003 PC2516
005 20210625062757.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aLeza, Juan Carlos
_91995
_eInstituto de Investigación i+12
100 _aMacDowell, Karina S.
_92610
_eInstituto de Investigación i+12
245 0 0 _aInflammatory activation and cholinergic anti-inflammatory system in eating disorders.
_h[artículo]
260 _bBrain Behavior and Immunity,
_c2013
300 _a32:33–9.
500 _aFormato Vancouver: MacDowell KS, Díaz-Marsá M, Güemes I, Rodríguez A, Leza JC, Carrasco JL. Inflammatory activation and cholinergic anti-inflammatory system in eating disorders. Brain Behav Immun. 2013;32:33–39.
501 _aPMID: 23624297
504 _aContiene 48 referencias
520 _aDysfunctional serotoninergic regulation and hypothalamic-pituitary-adrenal (HPA) axis overreactivity have been consistently reported in research studies with eating disorders (ED). In addition, the links between stress response, serotonin function, HPA axis and inflammatory mechanisms in ED have also been suggested in a number of studies. In our study, inflammatory parameters in white blood cells were investigated in 26 female patients with ED and 25 healthy control subjects matched for sex, age and ethnicity. Patients were free of medication for at least two weeks at the time of the study. Results showed a significant increase in plasma levels of the proinflammatory cytokine IL-1 beta and the protein expression of cyclooxygenase 2 (COX2) in peripheral mononuclear blood cells (PMBCs) in ED patients compared with controls. As well as a significant increase of the oxidative-nitrosative marker TBARS (Thiobarbituric Acid Reactive Substances) in plasma. These findings were associated with increased expression of the alpha7 subunit of the nicotinic receptor (alpha 7nAChR) in PMBC in ED patients independent of plasma cotinine levels. These results suggest that a pro-inflammatory and oxidant phenotype might be present in ED patients. Further research on cellular inflammatory and anti-inflammatory pathways might be oriented to investigate differences between ED subtypes and to search for new potential targets for pharmacological treatment.
710 _9625
_aInstituto de Investigación imas12
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/2/pc2516.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART